Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cell therapy (Lu Daopei Institute)
- Development stage
- Preclinical
- Lead developer
- Kecellitics Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
This anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is an investigational autologous cell therapy developed by the Lu Daopei Institute of Hematology in partnership with Kecellitics Biotech. The therapy utilizes T cells harvested from a patient, which are then genetically modified to express a CAR targeting the CD19 antigen, a protein consistently expressed on the surface of B-lineage cells. These engineered cells are expanded ex vivo and re-infused into the patient to identify and eliminate CD19-positive malignant cells. It is currently being evaluated for the treatment of B-cell leukemia, particularly in patients with relapsed or refractory disease.
- Other names
- anti-CD19 chimeric antigen receptor T cell therapyanti-CD-19 chimeric antigen receptor T cell therapyanti-CD 19 chimeric antigen receptor T cell therapyCD19-CAR-T cell therapyCD-19-CAR-T cell therapyCD 19-CAR-T cell therapyLu Daopei CD19 CAR-T
02
Targets
Beyond the preview
Go deeper on anti-CD19 CAR-T cell therapy (Lu Daopei Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cell therapy (Lu Daopei Institute).